Your browser doesn't support javascript.
Persistent depressive symptoms during COVID-19: a national, population-representative, longitudinal study of U.S. adults.
Ettman, Catherine K; Cohen, Gregory H; Abdalla, Salma M; Sampson, Laura; Trinquart, Ludovic; Castrucci, Brian C; Bork, Rachel H; Clark, Melissa A; Wilson, Ira; Vivier, Patrick M; Galea, Sandro.
  • Ettman CK; Boston University School of Public Health, Boston, MA, USA.
  • Cohen GH; Brown University School of Public Health, Providence, RI, USA.
  • Abdalla SM; Boston University School of Public Health, Boston, MA, USA.
  • Sampson L; Boston University School of Public Health, Boston, MA, USA.
  • Trinquart L; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Castrucci BC; Boston University School of Public Health, Boston, MA, USA.
  • Bork RH; de Beaumont Foundation, Bethesda, MD, USA.
  • Clark MA; de Beaumont Foundation, Bethesda, MD, USA.
  • Wilson I; Brown University School of Public Health, Providence, RI, USA.
  • Vivier PM; Brown University School of Public Health, Providence, RI, USA.
  • Galea S; Brown University School of Public Health, Providence, RI, USA.
Lancet Reg Health Am ; 5: 100091, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-2211030
ABSTRACT

BACKGROUND:

The COVID-19 pandemic and its consequences have been associated with an increase in poor population mental health. We assessed how depressive symptoms changed among U.S. adults over the course of the COVID-19 pandemic and identified the key risk factors for these symptoms.

METHODS:

Longitudinal panel study of a nationally representative group of U.S. adults ages 18 years and older surveyed in March-April 2020 (Time 1; N=1441) and March-April 2021 (Time 2; N=1161) in the COVID-19 and Life Stressors Impact on Mental Health and Well-being study (CLIMB). The Patient Health Questionnaire-9 (PHQ-9) was used to define elevated depressive symptoms (cut-off ≥10) and depressive symptoms score (0-27).

FINDINGS:

The prevalence of elevated depressive symptoms persisted from 27.8% in 2020 (95% CI 24.9, 30.9) to 32.8% in 2021 (95% CI 29.1, 36.8). Over time, the central drivers of depressive symptoms were low household income, not being married, and experiencing multiple stressors during the COVID-19 pandemic. The odds ratio of elevated depressive symptoms for low income relative to high income persons increased from 2.3 (95% CI 1.2, 4.2) in 2020 to 7.0 (95% CI 3.7, 13.3) in 2021. Fewer people reported experiencing 4 or more COVID-19 stressors in 2021 than in 2020 (47.5% in 2020 vs 37.1% in 2021), but the odds ratio of elevated depressive symptoms associated with 4 or more stressors relative to 1 stressor or less increased from 1.9 (95% CI 1.2, 3.1) in 2020 to 5.4 (95% CI 3.2, 9.2) in 2021.

INTERPRETATION:

The burden of depressive symptoms in the U.S. adult population increased over the course of the COVID-19 pandemic. Mental health gaps grew between populations with different assets and stressor experiences during the COVID-19 pandemic.

FUNDING:

CLIMB Time 1 was sponsored by the Rockefeller Foundation-Boston University 3-D Commission. CLIMB Time 2 was sponsored by the de Beaumont Foundation.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Qualitative research Topics: Long Covid Language: English Journal: Lancet Reg Health Am Year: 2022 Document Type: Article Affiliation country: J.lana.2021.100091

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Qualitative research Topics: Long Covid Language: English Journal: Lancet Reg Health Am Year: 2022 Document Type: Article Affiliation country: J.lana.2021.100091